-
Preclinical Tests May Lead to New Treatment Approach for CNS Lymphoma
Share this:
A drug recently approved for use in multiple myeloma is now being tested for its ability to fight central nervous system (CNS) lymphoma, a deadly cancer of the immune system that can affect the brain, spinal cord and fluid, and eyes. The clinical trial, now open on all three Mayo Clinic campuses — Florida, Minnesota and Arizona — follows successful testing of the drug, pomalidomide, in mouse models of CNS lymphoma.
Mayo Clinic oncologist Han Tun, M.D., says, “We believe pomalidomide could be beneficial in patients with this cancer because it does two things that most anti-cancer drugs do not do. The drug has excellent brain penetration, which is a requirement in treatment of brain tumors. The other interesting thing is that it is not only active directly against lymphoma cells but also alters the tumor microenvironment.”
Details of the preclinical testing are available in the science journal PLOS ONE.
Click here for news release
Related Articles
